^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AGX-148
i
Other names: AGX-148, AGX148, CD8 DP TIL, AGX 148
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AgonOx
Drug class:
IL-2 stimulant, T-cell stimulant, IL-12 stimulant
Related drugs:
1m
ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
AGX-148
over2years
ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, AgonOx, Inc.
New P1 trial • Metastases
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
AGX-148
over3years
Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762 (SITC 2022)
Conclusions We have generated a potent tumor-specific ACT TIL product (AGX148) at clinical scale through the isolation and selective expansion of tumor-reactive T cells. Knocking down PD-1 with PH-762 INTASYL™ has the potential to further enhance the function of the AGX148 product and this ACT product will soon be tested in cancer patients.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • ITGAE (Integrin Subunit Alpha E) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
AGX-148 • PH-762 ACT
Share via
